SGLT2 inhibitors: Trials such as EMPA-REG OUTCOME (empagliflozin) [40] and DAPA-HF (dapagliflozin) [41] have shown significant reductions in hospitalization for heart failure and cardiovascular mortality [42,43]. Here, SLC5A2 is linked to heart failure.